Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
8 "Protein kinase C"
Article category
Publication year
Original Article
Ruboxistaurin for the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review of Randomized Clinical Trials
Dipika Bansal, Yogesh Badhan, Kapil Gudala, Fabrizio Schifano
Diabetes Metab J. 2013;37(5):375-384.   Published online October 17, 2013
  • 5,084 View
  • 68 Download
  • 51 Crossref
AbstractAbstract PDFPubReader   

Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus. Protein kinase C (PKC) inhibitor's has been thought to be a potential disease modifying drug's in DPN as it slows or reverse neuropathy's progression. To assesses the efficacy and safety of ruboxistaurin on the progression of symptoms, signs, or functional disability in DPN.


A systematic review of the literature databases like PubMed, ProQuest, EBSCO, EMBASE, and Cochrane Central was performed up to August 2012. We included randomized controlled trials (RCTs) comparing PKC inhibitor ruboxistaurin (RBX) with control and lasting at least 6 months. Our primary outcome measure was change in neurological examination, measured by neurological total symptom score (NTSS) and vibration detection threshold (VDT). Secondary outcome measures were total quality of life (QoL), skin microvascular blood flow and others.


Six RCTs were included in review. Change in neurological function assessed by NTSS was reported in six studies, out of which significant difference between the RBX and placebo group seen in four studies favouring treatment group while remaining two studies reported no significant difference. VDT was assessed in only one study in which no significant difference seen between RBX and placebo group. Two studies reported significant improvement in QoL data. Safety data was reported in only two studies in which none of side effect was related to RBX.


RBX had effects on DPN in some studies, but the evidence is not enough for meta-analysis and firm conclusion.


Citations to this article as recorded by  
  • Painful Diabetic Neuropathy: The Need for New Approaches
    Andrea M. Yeung, Jingtong Huang, Kevin T. Nguyen, Nicole Y. Xu, Lorenzo T. Hughes, Brajesh K. Agrawal, Niels Ejskjaer, David C. Klonoff
    Journal of Diabetes Science and Technology.2024; 18(1): 159.     CrossRef
  • Cell metabolism pathways involved in the pathophysiological changes of diabetic peripheral neuropathy
    Yaowei Lv, Xiangyun Yao, Xiao Li, Yuanming Ouyang, Cunyi Fan, Yun Qian
    Neural Regeneration Research.2024; 19(3): 598.     CrossRef
  • Diabetic sensory neuropathy and insulin resistance are induced by loss of UCHL1 in Drosophila
    Daewon Lee, Eunju Yoon, Su Jin Ham, Kunwoo Lee, Hansaem Jang, Daihn Woo, Da Hyun Lee, Sehyeon Kim, Sekyu Choi, Jongkyeong Chung
    Nature Communications.2024;[Epub]     CrossRef
  • Non-Muscle Myosin IIC as a Prognostic and Therapeutic Target in Cancer
    Ghulam Jilany Khan, Sajal Salman, Zhu Chen, Song Li, Hui Chen, Yan Deng, Nongyue He
    Journal of Biomedical Nanotechnology.2024; 20(3): 438.     CrossRef
  • New Horizons in Diabetic Neuropathies: An Updated Review on their Pathology, Diagnosis, Mechanism, Screening Techniques, Pharmacological, and Future Approaches
    Namra Aziz, Biswajit Dash, Pranay Wal, Prachi Kumari, Poonam Joshi, Ankita wal
    Current Diabetes Reviews.2024;[Epub]     CrossRef
  • Nanoformulations of flavonoids for diabetes and microvascular diabetic complications
    Kopal Agarawal, Yogesh Anant Kulkarni, Sarika Wairkar
    Drug Delivery and Translational Research.2023; 13(1): 18.     CrossRef
  • Determination of Ruboxistaurin analysis in rat plasma utilizing LC–MS/MS technique
    Bushra T. AlQuadeib, Fadilah S. Aleanizy, Fulwah Y. Alqahtani, Rehab A. Alshammari, Amal Aldarwesh, Ibrahim Alsarra
    Saudi Pharmaceutical Journal.2023; 31(4): 547.     CrossRef
  • New perspectives in diabetic neuropathy
    Stephanie A. Eid, Amy E. Rumora, Bogdan Beirowski, David L. Bennett, Junguk Hur, Masha G. Savelieff, Eva L. Feldman
    Neuron.2023; 111(17): 2623.     CrossRef
  • Issues and challenges in diabetic neuropathy management: A narrative review
    Che Aishah Nazariah Ismail
    World Journal of Diabetes.2023; 14(6): 741.     CrossRef
  • Plasma Metabolomics and Lipidomics Differentiate Obese Individuals by Peripheral Neuropathy Status
    Kai Guo, Masha G Savelieff, Amy E Rumora, Fadhl M Alakwaa, Brian C Callaghan, Junguk Hur, Eva L Feldman
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(4): 1091.     CrossRef
  • The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy
    Seyed Hossein Aghamiri, Khalil Komlakh, Mehran Ghaffari
    Inflammopharmacology.2022; 30(1): 51.     CrossRef
  • 10.6-μm infrared laser as adjuvant therapy for diabetic peripheral neuropathy: study protocol for a double-blind, randomized controlled trial
    Lin Lin, Yi Chen, Yuxia Li, Ke Cheng, Haiping Deng, Jianping Lu, Ling Zhao, Xueyong Shen
    Trials.2022;[Epub]     CrossRef
  • Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?
    Dalal Y. Al-Bazz, Andrew J. Nelson, Jamie Burgess, Ioannis N. Petropoulos, Jael Nizza, Anne Marshall, Emily Brown, Daniel J. Cuthbertson, Andrew G. Marshall, Rayaz A. Malik, Uazman Alam
    Diagnostics.2022; 12(3): 731.     CrossRef
  • Prospective dietary radical scavengers: Boon in Pharmacokinetics, overcome insulin obstruction via signaling cascade for absorption during impediments in metabolic disorder like Diabetic Mellitus
    Varuna Suresh, John Kunnath, Amala Reddy
    Journal of Diabetes & Metabolic Disorders.2022; 21(1): 1149.     CrossRef
  • The Treatment of Painful Diabetic Neuropathy
    Gordon Sloan, Uazman Alam, Dinesh Selvarajah, Solomon Tesfaye
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Effect of Cognitive-Behavioral Therapy or Mindfulness Therapy on Pain and Quality of Life in Patients with Diabetic Neuropathy: A Systematic Review and Meta-Analysis
    Yuan Bai, Jun-Hong Ma, Ying Yu, Zhi-Wen Wang
    Pain Management Nursing.2022; 23(6): 861.     CrossRef
  • Emerging drugs for the treatment of diabetic nephropathy
    Yoon Kook Kim, Xinyuan Ning, Kashif M. Munir, Stephen N. Davis
    Expert Opinion on Emerging Drugs.2022; 27(4): 417.     CrossRef
  • Novel treatment modalities for painful diabetic neuropathy
    A. Rastogi, E.B. Jude
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 287.     CrossRef
  • Effectiveness and safety of low-level laser therapy in diabetic peripheral neuropathy: a protocol for a systematic review and meta-analysis
    Lin Lin, Jingjing Li, Jingshan Lin, Shiheng Tang, Yuxia Li
    Systematic Reviews.2021;[Epub]     CrossRef
  • Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes
    Amy E. Rumora, Kai Guo, Fadhl M. Alakwaa, Signe T. Andersen, Evan L. Reynolds, Marit E. Jørgensen, Daniel R. Witte, Hatice Tankisi, Morten Charles, Masha G. Savelieff, Brian C. Callaghan, Troels S. Jensen, Eva L. Feldman
    Annals of Clinical and Translational Neurology.2021; 8(6): 1292.     CrossRef
  • Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
    Gordon Sloan, Dinesh Selvarajah, Solomon Tesfaye
    Nature Reviews Endocrinology.2021; 17(7): 400.     CrossRef
  • Diabetic neuropathy: an insight on the transition from synthetic drugs to herbal therapies
    Komal Arora, Pushpa C. Tomar, Vandana Mohan
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1773.     CrossRef
  • Synthesis and Antiplasmodial Activity of Bisindolylcyclobutenediones
    Duc Hoàng Lande, Abed Nasereddin, Arne Alder, Tim W. Gilberger, Ron Dzikowski, Johann Grünefeld, Conrad Kunick
    Molecules.2021; 26(16): 4739.     CrossRef
  • High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy
    Chialin Cheng, Surya A. Reis, Emily T. Adams, Daniel M. Fass, Steven P. Angus, Timothy J. Stuhlmiller, Jared Richardson, Hailey Olafson, Eric T. Wang, Debasis Patnaik, Roberta L. Beauchamp, Danielle A. Feldman, M. Catarina Silva, Mriganka Sur, Gary L. Joh
    Scientific Reports.2021;[Epub]     CrossRef
  • Management of diabetic neuropathy
    Simona Cernea, Itamar Raz
    Metabolism.2021; 123: 154867.     CrossRef
  • 29th Annual GP2A Medicinal Chemistry Conference
    Jean-Jacques Helesbeux, Laura Carro, Florence O. McCarthy, Vânia M. Moreira, Francesca Giuntini, Niamh O’Boyle, Susan E. Matthews, Gülşah Bayraktar, Samuel Bertrand, Christophe Rochais, Pascal Marchand
    Pharmaceuticals.2021; 14(12): 1278.     CrossRef
  • Understanding Diabetic Neuropathy: Focus on Oxidative Stress
    Lei Pang, Xin Lian, Huanqiu Liu, Yuan Zhang, Qian Li, Yin Cai, Haichun Ma, Xin Yu
    Oxidative Medicine and Cellular Longevity.2020; 2020: 1.     CrossRef
  • Treatment of Diabetic Cardiovascular Autonomic, Peripheral and Painful Neuropathy. Focus on the Treatment of Cardiovascular Autonomic Neuropathy with ACE Inhibitors
    Triantafyllos Didangelos, Aristidis Veves
    Current Vascular Pharmacology.2020; 18(2): 158.     CrossRef
  • Mechanisms of small nerve fiber pathology
    Franziska Gross, Nurcan Üçeyler
    Neuroscience Letters.2020; 737: 135316.     CrossRef
  • Whole-Genome Sequencing of Finnish Type 1 Diabetic Siblings Discordant for Kidney Disease Reveals DNA Variants associated with Diabetic Nephropathy
    Jing Guo, Owen J. L. Rackham, Niina Sandholm, Bing He, Anne-May Österholm, Erkka Valo, Valma Harjutsalo, Carol Forsblom, Iiro Toppila, Maija Parkkonen, Qibin Li, Wenjuan Zhu, Nathan Harmston, Sonia Chothani, Miina K. Öhman, Eudora Eng, Yang Sun, Enrico Pe
    Journal of the American Society of Nephrology.2020; 31(2): 309.     CrossRef
  • SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice
    Xialin Zhu, Yun Chen, Xu Xu, Xiaoju Xu, Yin Lu, Xi Huang, Jinpei Zhou, Lihong Hu, Jiaying Wang, Xu Shen
    EBioMedicine.2020; 61: 103061.     CrossRef
  • Targeting Mitochondrial Fission-Fusion Imbalance in Heart Failure
    Thiago N. Menezes, Lisley S. Ramalho, Luiz R. G. Bechara, Julio Cesar Batista Ferreira
    Current Tissue Microenvironment Reports.2020; 1(4): 239.     CrossRef
  • Recent advances in the pathogenesis of microvascular complications in diabetes
    Sungmi Park, Hyeon-Ji Kang, Jae-Han Jeon, Min-Ji Kim, In-Kyu Lee
    Archives of Pharmacal Research.2019; 42(3): 252.     CrossRef
  • Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
    Neeraj Kumar, Anita Singh, Dinesh Kumar Sharma, Kamal Kishore
    Current Signal Transduction Therapy.2019; 14(2): 107.     CrossRef
  • Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
    Saikat Dewanjee, Sonjit Das, Anup Kumar Das, Niloy Bhattacharjee, Anjum Dihingia, Tarun K. Dua, Jatin Kalita, Prasenjit Manna
    European Journal of Pharmacology.2018; 833: 472.     CrossRef
  • Interventions for Neuropathic Pain: An Overview of Systematic Reviews
    Svjetlana Dosenovic, Antonia Jelicic Kadic, Maja Miljanovic, Marina Biocic, Krste Boric, Marija Cavar, Nikolina Markovina, Katarina Vucic, Livia Puljak
    Anesthesia & Analgesia.2017; 125(2): 643.     CrossRef
  • New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
    Eva L. Feldman, Klaus-Armin Nave, Troels S. Jensen, David L.H. Bennett
    Neuron.2017; 93(6): 1296.     CrossRef
  • Rutin suppresses high glucose-induced ACTA2 and p38 protein expression in diabetic nephropathy
    Chun-Shan Han, Kai Liu, Ning Zhang, Shi-Wen Li, Hai-Cheng Gao
    Experimental and Therapeutic Medicine.2017; 14(1): 181.     CrossRef
  • Protein kinase C participation in the mechanisms of vascular tone disturbance upon diabetes mellitus. Part 4
    I. Kizub, O. Kharchenko, O. Kostiuk, L. Ostapchenko, K. Klymenko, A. Soloviev
    Bulletin of Taras Shevchenko National University of Kyiv. Series: Problems of Physiological Functions Regulation.2016; 21(2): 61.     CrossRef
  • Emerging drugs for diabetic peripheral neuropathy and neuropathic pain
    Nikolaos Papanas, Dan Ziegler
    Expert Opinion on Emerging Drugs.2016; 21(4): 393.     CrossRef
  • Pancreatic β Cell Mass Death
    Husnia I. Marrif, Salma I. Al-Sunousi
    Frontiers in Pharmacology.2016;[Epub]     CrossRef
  • Efficacy and safety of prostaglandin E1 plus lipoic acid combination therapy versus monotherapy for patients with diabetic peripheral neuropathy
    De-Qi Jiang, Ming-Xing Li, Yan-Jiao Ma, Yan Wang, Yong Wang
    Journal of Clinical Neuroscience.2016; 27: 8.     CrossRef
  • Nonbiological pharmacotherapies for the treatment of diabetic macular edema
    Aniruddha Agarwal, Jacob Parriott, Sibel Demirel, Colby Argo, Yasir Jamal Sepah, Diana V Do, Quan Dong Nguyen
    Expert Opinion on Pharmacotherapy.2015; 16(17): 2625.     CrossRef
  • Present and Future in the Treatment of Diabetic Kidney Disease
    Borja Quiroga, David Arroyo, Gabriel de Arriba
    Journal of Diabetes Research.2015; 2015: 1.     CrossRef
  • Choosing drugs for the treatment of diabetic neuropathy
    Majed Alabdali, Mohammad Qrimli, Carolina Barnett, Alon Abraham, Ari Breiner, Hans D Katzberg, Danah Aljaafari, Hana Albulaihe, Bruce A Perkins, Vera Bril
    Expert Opinion on Pharmacotherapy.2015; 16(12): 1805.     CrossRef
  • Burning through the pain: treatments for diabetic neuropathy
    S. Javed, U. Alam, R. A. Malik
    Diabetes, Obesity and Metabolism.2015; 17(12): 1115.     CrossRef
  • Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220
    Abdullah Mayati, Arnaud Bruyere, Amélie Moreau, Elodie Jouan, Claire Denizot, Yannick Parmentier, Olivier Fardel, Jeff M Sands
    PLOS ONE.2015; 10(12): e0144667.     CrossRef
  • Targeting caveolin-3 for the treatment of diabetic cardiomyopathy
    Lucy Murfitt, Gareth Whiteley, Mohammad M. Iqbal, Ashraf Kitmitto
    Pharmacology & Therapeutics.2015; 151: 50.     CrossRef
  • Protein kinase C in enhanced vascular tone in diabetes mellitus
    Igor V. Kizub, Kateryna I. Klymenko, Anatoly I. Soloviev
    International Journal of Cardiology.2014; 174(2): 230.     CrossRef
  • Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy
    Houliang Deng, JinJin Yin, JingJing Zhang, Qian Xu, Xiaoxia Liu, Li Liu, Zhuomin Wu, Aimin Ji
    Endocrine.2014; 46(3): 445.     CrossRef
  • Efficacy of α-lipoic acid in diabetic neuropathy
    Nikolaos Papanas, Dan Ziegler
    Expert Opinion on Pharmacotherapy.2014; 15(18): 2721.     CrossRef
The Role of Oxidative Stress in the Pathogenesis of Diabetic Vascular Complications
Shuji Sasaki, Toyoshi Inoguchi
Diabetes Metab J. 2012;36(4):255-261.   Published online August 20, 2012
  • 4,111 View
  • 65 Download
  • 60 Crossref
AbstractAbstract PDFPubReader   

Oxidative stress has been paid increasing attention to as an important causative factor for diabetic vascular complications. Among possible various sources, accumulating evidence has indicated that NAD(P)H oxidase may be the most important source for reactive oxygen species production in diabetic vascular tissues. The mechanisms underlying activation and up-regulation of NAD(P)H oxidase has been supposed to be mediated by high glucose-induced protein kinase C (PKC) activation. In this review article, activation of local renin-angiotensin II system induced by chymase activation is also shown to amplify such a PKC-dependent activation of NAD(P)H oxidase. Additionally, human evidence showing the beneficial effect of antioxidants on diabetic vascular complications. Bilirubin has been recognized as a strong endogenous antioxidant. Here markedly lower prevalence of vascular complications is shown in diabetic patients with Gilbert syndrome, a congenital hyperbilirubinemia, as well as reduced markers of oxidative stress and inflammation. Lastly, statin, angiotensin II receptor blocker, chymase inhibitor, bilirubin and biliverdin, PKC β isoform inhibitor, and glucagon-like peptide-1 analog, are shown to serve as antioxidants and have some beneficial effect on diabetic vascular complications, via inhibiting PKC-NAD(P)H oxidase activation, supporting the notion that this mechanism may be an effective therapeutic target for preventing diabetic vascular complications.


Citations to this article as recorded by  
  • The effects of whey protein on anthropometric parameters, resting energy expenditure, oxidative stress, and appetite in overweight/obese women with type 2 diabetes mellitus: A randomized placebo controlled clinical trial
    Maryam Nouri, Bahram Pourghassem Gargari, Zahra Ghasempour, Vahideh Sadra, Mohammad Asghari Jafarabadi, Arvin Babaei, Pedram Tajfar, Ali Tarighat-Esfanjani
    International Journal of Diabetes in Developing Countries.2024; 44(1): 155.     CrossRef
  • Rhodanine-benzamides as potential hits for α-amylase enzyme inhibitors and radical (DPPH and ABTS) scavengers
    Samuel Attah Egu, Irfan Ali, Khalid Mohammed Khan, Sridevi Chigurupati, Urooj Qureshi, Uzma Salar, Zaheer Ul-Haq, Suliman A. Almahmoud, Shatha Ghazi Felemban, Mohsin Ali, Muhammad Taha
    Molecular Diversity.2024;[Epub]     CrossRef
  • Research Progress of FGF-21 and CVAI in Type 2 Diabetic Kidney Disease
    央宗 才巴
    Advances in Clinical Medicine.2023; 13(07): 12056.     CrossRef
  • Is Subcutaneous Rifamycin Application Superior to Saline Application in Hip Hemiarthroplasty?
    Malik Çelik, Nezih Ziroğlu, Alkan Bayrak
    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy.2023; 19(2): 186.     CrossRef
  • In pursuit of incorporation of markers of oxidative stress in traditional biochemical panels in clinical Chemistry: A risk assessment step in diagnosis and biotherapy
    John Ibhagbemien Anetor, Chukwuemelie Zedech Uche, Gloria Oiyahumen Anetor
    American Journal of Biopharmacy and Pharmaceutical Sciences.2022; 2: 1.     CrossRef
  • Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
    Chan-Young Jung, Tae-Hyun Yoo
    Diabetes & Metabolism Journal.2022; 46(2): 181.     CrossRef
  • p38 MAPK Inhibitor (SB203580) and Metformin Reduces Aortic Protein Carbonyl and Inflammation in Non-obese Type 2 Diabetic Rats
    Nuttikarn Nokkaew, Podsawee Mongkolpathumrat, Ruttanapong Junsiri, Supawit Jindaluang, Nichagron Tualamun, Niya Manphatthanakan, Nareumon Saleesee, Marisa Intasang, Jantira Sanit, Punyanuch Adulyaritthikul, Kantapich Kongpol, Sarawut Kumphune, Nitirut Ner
    Indian Journal of Clinical Biochemistry.2021; 36(2): 228.     CrossRef
  • Resveratrol-Elicited PKC Inhibition Counteracts NOX-Mediated Endothelial to Mesenchymal Transition in Human Retinal Endothelial Cells Exposed to High Glucose
    Roberta Giordo, Gheyath K. Nasrallah, Anna Maria Posadino, Francesco Galimi, Giampiero Capobianco, Ali Hussein Eid, Gianfranco Pintus
    Antioxidants.2021; 10(2): 224.     CrossRef
    Ugiloy Yusufovna Yusupova, Nurmurod Sheralievich Ramazonov, Khairulla Mamadievich Bobakulov, Feruza Rustamovna Egamova, Vladimir Nikolaevich Syrov, Durbek Abdikhoshimovich Usmanov
    chemistry of plant raw material.2021; (1): 197.     CrossRef
  • Chronically Elevated Exogenous Glucose Elicits Antipodal Effects on the Proteome Signature of Differentiating Human iPSC-Derived Pancreatic Progenitors
    Luiza Ghila, Thomas Aga Legøy, Andreas Frøslev Mathisen, Shadab Abadpour, Joao A. Paulo, Hanne Scholz, Helge Ræder, Simona Chera
    International Journal of Molecular Sciences.2021; 22(7): 3698.     CrossRef
  • Effect of Type-2 Diabetes Mellitus in Retinopathy Patients on MDA, SOD Activity and its Correlation with HbA1c
    Yali Hou, Mei Lin, Xuan Qiu, Mingjuan He, Yu Zhang, Feifei Guo
    Brazilian Archives of Biology and Technology.2021;[Epub]     CrossRef
  • Ameliorative effects of Hydrolea zeylanica in streptozotocin-induced oxidative stress and metabolic changes in diabetic rats
    Sandeep Kumar Swain, Umesh Chandra Dash, Satish Kanhar, Atish Kumar Sahoo
    Journal of Ethnopharmacology.2020; 247: 112257.     CrossRef
  • Imbalance in the antioxidant defence system and pro-genotoxic status induced by high glucose concentrations: In vitro testing in human liver cells
    Mattia Acito, Desirée Bartolini, Maria Rachele Ceccarini, Carla Russo, Samuele Vannini, Luca Dominici, Michela Codini, Milena Villarini, Francesco Galli, Tommaso Beccari, Massimo Moretti
    Toxicology in Vitro.2020; 69: 105001.     CrossRef
  • Synthesis of sulpha drug based hydroxytriazene derivatives: Anti-diabetic, antioxidant, anti-inflammatory activity and their molecular docking studies
    Poonam Sharma, Varsha Dayma, Aparna Dwivedi, Prabhat K. Baroliya, I.P. Tripathi, Murugesan Vanangamudi, R.S. Chauhan, A.K. Goswami
    Bioorganic Chemistry.2020; 96: 103642.     CrossRef
  • Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells
    Erqin Xu, Xiaolei Hu, Xiaoli Li, Guoxi Jin, Langen Zhuang, Qiong Wang, Xiaoyan Pei
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Potent α-amylase inhibitors and radical (DPPH and ABTS) scavengers based on benzofuran-2-yl(phenyl)methanone derivatives: Syntheses, in vitro, kinetics, and in silico studies
    Irfan Ali, Rafaila Rafique, Khalid Mohammed Khan, Sridevi Chigurupati, Xingyue Ji, Abdul Wadood, Ashfaq Ur Rehman, Uzma Salar, Muhammad Shahid Iqbal, Muhammad Taha, Shahnaz Perveen, Basharat Ali
    Bioorganic Chemistry.2020; 104: 104238.     CrossRef
  • A review of fibroblast growth factor 21 in diabetic cardiomyopathy
    Xiang Zhang, Luo Yang, Xiongfeng Xu, Fengjuan Tang, Peng Yi, Bo Qiu, Yarong Hao
    Heart Failure Reviews.2019; 24(6): 1005.     CrossRef
  • Recent advances in the pathogenesis of microvascular complications in diabetes
    Sungmi Park, Hyeon-Ji Kang, Jae-Han Jeon, Min-Ji Kim, In-Kyu Lee
    Archives of Pharmacal Research.2019; 42(3): 252.     CrossRef
  • Metabolic syndrome status over 2 years predicts incident chronic kidney disease in mid-life adults: a 10-year prospective cohort study
    So Jin Lee, Hun Ju Lee, Hyun jeong Oh, Taehwa Go, Dae Ryong Kang, Jang Young Kim, Ji Hye Huh
    Scientific Reports.2018;[Epub]     CrossRef
  • Role of peroxisome proliferator–activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus
    A Tabassum, T Mahboob
    Human & Experimental Toxicology.2018; 37(11): 1187.     CrossRef
  • Coffee consumption and reduced risk of developing type 2 diabetes: a systematic review with meta-analysis
    Mattias Carlström, Susanna C Larsson
    Nutrition Reviews.2018; 76(6): 395.     CrossRef
  • Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model
    Pin Chen, Xiaozhi Shi, Xiangjin Xu, Yiyang Lin, Zhulin Shao, Rongdan Wu, Lihong Huang
    Diabetes Research and Clinical Practice.2018; 137: 173.     CrossRef
  • Antioxidant effects of vitamins in type 2 diabetes: a meta-analysis of randomized controlled trials
    Maria E. Balbi, Fernanda S. Tonin, Antonio M. Mendes, Helena H. Borba, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo
    Diabetology & Metabolic Syndrome.2018;[Epub]     CrossRef
  • Gilbert syndrome in patients with type 1 diabetes-Prevalence, glycemic control, and microalbuminuria
    Sigal Singer, Nurit Pilpel, Orit Pinhas-Hamiel
    Pediatric Diabetes.2017; 18(8): 803.     CrossRef
  • Low serum bilirubin level predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus
    Kang Hee Ahn, Sang Soo Kim, Won Jin Kim, Jong Ho Kim, Yun Jeong Nam, Su Bin Park, Yun Kyung Jeon, Bo Hyun Kim, In Joo Kim, Yong Ki Kim
    The Korean Journal of Internal Medicine.2017; 32(5): 875.     CrossRef
  • Tiron ameliorates high glucose‐induced cardiac myocyte apoptosis by PKCδ‐dependent inhibition of osteopontin
    Ping Jiang, Deling Zhang, Hong Qiu, Xianqi Yi, Yemin Zhang, Yingkang Cao, Bo Zhao, Zhongyuan Xia, Changhua Wang
    Clinical and Experimental Pharmacology and Physiology.2017; 44(7): 760.     CrossRef
  • Protective effects of 6-Gingerol on vascular endothelial cell injury induced by high glucose via activation of PI3K-AKT-eNOS pathway in human umbilical vein endothelial cells
    Dan Liu, Mengqing Wu, Yi Lu, Tao Xian, Yupeng Wang, Bowei Huang, Guohua Zeng, Qiren Huang
    Biomedicine & Pharmacotherapy.2017; 93: 788.     CrossRef
  • Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
    Maria Peleli, Mattias Carlstrom
    Molecular Aspects of Medicine.2017; 55: 62.     CrossRef
  • Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients
    Alliny de Souza Bastos, Dana T. Graves, Ana Paula de Melo Loureiro, Carlos Rossa Júnior, Sâmia Cruz Tfaile Corbi, Fausto Frizzera, Raquel Mantuaneli Scarel-Caminaga, Niels Olsen Câmara, Oelisoa M. Andriankaja, Meire I. Hiyane, Silvana Regina Perez Orrico
    Journal of Diabetes and its Complications.2016; 30(8): 1593.     CrossRef
  • Agkistrodon acutus-purified protein C activator protects human umbilical vein endothelial cells against H2O2-induced apoptosis
    Shu Li, Yun Hong, Xin Jin, Xianwei Li, Entao Sun, Genbao Zhang, Linming Lu, Liuwang Nie
    Pharmaceutical Biology.2016; 54(12): 3285.     CrossRef
  • The impact of mast cells on cardiovascular diseases
    Eva Kritikou, Johan Kuiper, Petri T. Kovanen, Ilze Bot
    European Journal of Pharmacology.2016; 778: 103.     CrossRef
  • Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity
    Weiping Sun, Chunping Zeng, Lizhen Liao, Juan Chen, Ying Wang
    Current Medical Research and Opinion.2016; 32(8): 1389.     CrossRef
  • Mechanisms for the cardiovascular effects of glucagon-like peptide-1
    H. Poudyal
    Acta Physiologica.2016; 216(3): 277.     CrossRef
  • Integrated scientific data bases review on asulacrine and associated toxicity
    Attia Afzal, Muhammad Sarfraz, Zimei Wu, Guangji Wang, Jianguo Sun
    Critical Reviews in Oncology/Hematology.2016; 104: 78.     CrossRef
  • Impact of Diabetes and Defective Thyroid Ontogenesis on Audition
    Luciene da Cruz Fernandes
    Journal of Diabetes, Metabolic Disorders & Control.2016;[Epub]     CrossRef
  • Serum Total Bilirubin Levels Provide Additive Risk Information over the Framingham Risk Score for Identifying Asymptomatic Diabetic Patients at Higher Risk for Coronary Artery Stenosis
    Jaechan Leem, Eun Hee Koh, Jung Eun Jang, Chang-Yun Woo, Jin Sun Oh, Min Jung Lee, Joon-Won Kang, Tae-Hwan Lim, Chang Hee Jung, Woo Je Lee, Joong-Yeol Park, Ki-Up Lee
    Diabetes & Metabolism Journal.2015; 39(5): 414.     CrossRef
  • Clinical implications of carotid artery intima media thickness assessment on cardiovascular risk stratification in hyperlipidemic Korean adults with diabetes: the ALTO study
    Eun-Gyoung Hong, Jung Hun Ohn, Seong Jin Lee, Hyuk Sang Kwon, Sin Gon Kim, Dong Jun Kim, Dong Sun Kim
    BMC Cardiovascular Disorders.2015;[Epub]     CrossRef
  • Undiagnosed diabetes is prevalent in younger adults and associated with a higher risk cardiometabolic profile compared to diagnosed diabetes
    Yong-ho Lee, Ehrin J. Armstrong, Gyuri Kim, Jaewon Oh, Seok-Min Kang, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Christos S. Mantzoros, Eun Seok Kang
    American Heart Journal.2015; 170(4): 760.     CrossRef
  • Common Polymorphisms in Antioxidant Genes are Associated with Diabetic Nephropathy in Type 2 Diabetes Patients
    Jasna Klen, Katja Goričar, Andrej Janež, Vita Dolžan
    Personalized Medicine.2015; 12(3): 187.     CrossRef
  • Increased endogenous serotonin level in diabetic conditions may lead to cardiac valvulopathy via reactive oxygen species regulation
    Tahir Ali, Hina Waheed, Farhat Shaheen, Madiha Mahmud, Qamar Javed, Iram Murtaza
    Biologia.2015; 70(2): 273.     CrossRef
  • Antioxidant Effects of Statins in the Management of Cardiometabolic Disorders
    Soo Lim, Philip Barter
    Journal of Atherosclerosis and Thrombosis.2014; 21(10): 997.     CrossRef
  • Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
    Stanley Schwartz
    Postgraduate Medicine.2014; 126(3): 66.     CrossRef
  • Low serum bilirubin concentration is a novel risk factor for the development of albuminuria in patients with type 2 diabetes
    Hiroshi Okada, Michiaki Fukui, Muhei Tanaka, Shinobu Matsumoto, Kanae Kobayashi, Hiroya Iwase, Kiichiro Tomiyasu, Koji Nakano, Goji Hasegawa, Naoto Nakamura
    Metabolism.2014; 63(3): 409.     CrossRef
  • Serum total bilirubin levels and prevalence of diabetic retinopathy in a Chinese population (中国人群血清总胆红素水平与糖尿病视网膜病变相关性的研究)
    Syeda Sadia Najam, Jichao Sun, Jie Zhang, Min Xu, Jieli Lu, Kan Sun, Mian Li, Tiange Wang, Yufang Bi, Guang Ning
    Journal of Diabetes.2014; 6(3): 221.     CrossRef
  • Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk
    Morihiro Matsuda, Iichiro Shimomura
    Hormone Molecular Biology and Clinical Investigation.2014;[Epub]     CrossRef
  • Unilateral injection of Aβ25–35 in the hippocampus reduces the number of dendritic spines in hyperglycemic rats
    Zayda Lazcano, Oscar Solis, María Elena Bringas, Daniel Limón, Alfonso Diaz, Blanca Espinosa, Isabel García‐Peláez, Gonzalo Flores, Jorge Guevara
    Synapse.2014; 68(12): 585.     CrossRef
  • Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications
    Vaibhav B. Patel, Nirmal Parajuli, Gavin Y. Oudit
    Clinical Science.2014; 126(7): 471.     CrossRef
  • Pathogenesis of Chronic Hyperglycemia: From Reductive Stress to Oxidative Stress
    Liang-Jun Yan
    Journal of Diabetes Research.2014; 2014: 1.     CrossRef
  • Daily intake of vitamin D‐ or calcium‐vitamin D‐fortified Persian yogurt drink (doogh) attenuates diabetes‐induced oxidative stress: evidence for antioxidative properties of vitamin D
    B. Nikooyeh, T. R. Neyestani, N. Tayebinejad, H. Alavi‐Majd, N. Shariatzadeh, A. Kalayi, M. Zahedirad, S. Heravifard, S. Salekzamani
    Journal of Human Nutrition and Dietetics.2014; 27(s2): 276.     CrossRef
  • Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases
    Morihiro Matsuda, Iichiro Shimomura
    Reviews in Endocrine and Metabolic Disorders.2014; 15(1): 1.     CrossRef
  • PKCδ-dependent Activation of the Ubiquitin Proteasome System is Responsible for High Glucose-induced Human Breast Cancer MCF-7 Cell Proliferation, Migration and Invasion
    Shan Zhu, Feng Yao, Wen-Huan Li, Jin-Nan Wan, Yi-Min Zhang, Zhao Tang, Shahzad Khan, Chang-Hua Wang, Sheng-Rong Sun
    Asian Pacific Journal of Cancer Prevention.2013; 14(10): 5687.     CrossRef
  • Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer
    Morihiro Matsuda, Iichiro Shimomura
    Obesity Research & Clinical Practice.2013; 7(5): e330.     CrossRef
  • Hydrogen Sulfide Suppresses High Glucose–Induced Expression of Intercellular Adhesion Molecule-1 in Endothelial Cells
    Qingbo Guan, Xiaolei Wang, Ling Gao, Jicui Chen, Yuantao Liu, Chunxiao Yu, Nan Zhang, Xu Zhang, Jiajun Zhao
    Journal of Cardiovascular Pharmacology.2013; 62(3): 278.     CrossRef
  • Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus
    Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
    Diabetes & Metabolism Journal.2013; 37(6): 423.     CrossRef
  • Glucose initially inhibits and later stimulates blood ROS generation
    Thomas Stief
    Journal of Diabetes Mellitus.2013; 03(01): 15.     CrossRef
  • Oxidative Stress in Cardiovascular Diseases and Obesity: Role of p66Shc and Protein Kinase C
    Elena De Marchi, Federica Baldassari, Angela Bononi, Mariusz R. Wieckowski, Paolo Pinton
    Oxidative Medicine and Cellular Longevity.2013; 2013: 1.     CrossRef
  • Toxicological and pharmacological concerns on oxidative stress and related diseases
    Soodabeh Saeidnia, Mohammad Abdollahi
    Toxicology and Applied Pharmacology.2013; 273(3): 442.     CrossRef
  • Comparison of antioxidant, α-glucosidase inhibition and anti-inflammatory activities of the leaf and root extracts ofSmilax chinaL.
    Kyoung Kon Kim, Yun Hwan Kang, Dae Jung Kim, Tae Woo Kim, Myeon Choe
    Journal of Nutrition and Health.2013; 46(4): 315.     CrossRef
  • Correlation between blood glucose fluctuations and activation of oxidative stress in type 1 diabetic children during the acute metabolic disturbance period
    Di WU, Chun-xiu GONG, Xi MENG, Qiu-lan YANG
    Chinese Medical Journal.2013; 126(21): 4019.     CrossRef
  • Oxidative stress and its complications in human health
    Guniz M. Koksal
    Advances in Bioscience and Biotechnology.2012; 03(08): 1113.     CrossRef
Original Articles
Migration of Vascular Smooth Muscle Cells by High Glucose is Reactive Oxygen Dependent.
Yong Seong An, Ji Hae Kwon, Yang Ho Kang, In Ju Kim, Yong Ki Kim, Seok Man Son
Korean Diabetes J. 2008;32(3):185-195.   Published online June 1, 2008
  • 2,020 View
  • 17 Download
AbstractAbstract PDF
Oxidative stress contributes to vascular diseases in patients with diabetes. As the mechanism of development and progression of diabetic vascular complications is poorly understood, this study was aimed to assess the potential role of hyperglycemia-induced oxidative stress and to determine whether the oxidative stress is a major factor in hyperglycemia-induced migration of vascular smooth muscle cells (VSMCs). METHODS: We treated primary cultured rat aortic smooth muscle cells for 72 hours with medium containing 5.5 mM D-glucose (normal glucose), 30 mM D-glucose (high glucose) or 5.5 mM D-glucose plus 24.5 mM mannitol (osmotic control). We measured the migration of VSMCs and superoxide production. Immunoblotting of PKC isozymes using phoshospecific antibodies was performed, and PKC activity was also measured. RESULTS: Migration of VSMCs incubated under high glucose condition were markedly increased compared to normal glucose condition. Treatment with diphenyleneiodonium (DPI, 10 micromol/L) and superoxide dismutase (SOD, 500 U/mL) significantly suppressed high glucose-induced migration of VSMCs. Superoxide production was significantly increased in high glucose condition and was markedly decreased after treatment with DPI and SOD. High glucose also markedly increased activity of PKC-delta isozyme. When VSMCs were treated with rottlerin or transfected with PKC-delta siRNA, nitro blue tetrazolium (NBT) staining and NAD(P)H oxidase activity were significantly attenuated in the high glucose-treated VSMCs. Furthermore, inhibition of PKC-delta markedly decreased VSMC migration by high glucose. CONCLUSION: These results suggest that high glucose-induced VSMC migration is dependent upon activation of PKC-delta, which may responsible for elevated intracellular ROS production in VSMCs, and this is mediated by NAD(P)H oxidase.
Cell Cycle Progression of Vascular Smooth Muscle cell Through Modulation of p38 MAPK and GSK-3beta Activities Under High Glucose Condition.
Yang Ho Kang, In Ju Kim, Yong Ki Kim, Seok Man Son
Korean Diabetes J. 2005;29(5):418-431.   Published online September 1, 2005
  • 845 View
  • 18 Download
AbstractAbstract PDF
BACKGOUND: Macroangiopathy, with atherosclerosis, is the leading cause of mortality and morbidity in diabetic patients. Vascular smooth muscle cells play a crucial role in atherosclerosis, as they proliferate, migrate and express genes that encode inducible growth factors. However, the mechanisms induced by hyperglycemia that accelerate the proliferative change of vascular smooth muscle cells in diabetes remain unclear. This study was aimed at clarifying the respective roles of hyperglycemia in the acceleration of vascular complications in diabetes, examine the effects of hyperglycemia on vascular smooth muscle cell proliferation and the possible underlying mechanisms, including cell cycle progression. METHODS: Primary cultured rat aortic RASMs were exposed to normal glucose(5 mmol/L D-glucose), high glucose(30 mmol/L D-glucose) or an osmotic control (5mmol/L D-glucose plus 24.5 mmol/L mannitol) for 72 hours. The effect of high glucose on cell proliferation was determined by assessing the cell count and BrdU incorporation. Proteins involved in the cell proliferation pathway (PDK1, Akt/PKB, p42/44 MAPK, p38 MAPK, GSK-3beta) and those in cell cycle progression (cdk4, cyclin D, cdk2, cyclin E and ppRb phosphorylation) were determined by Western blot analysis. cdk4 kinase and PKC activity assays were also performed. RESULTS: A high level of glucose increased both the cell count(P<0.01) and BrdU incorporation(P<0.01). The PDK1, Akt/PKB and p42/44 MAPK activities were not significantly increased. A high level of glucose significantly increased the activities of p38 MAPK (P<0.01) and GSK-3beta(P<0.05) and the expressions of cdk4, cyclin D and ppRb phosphorylation. The cdk4 (P<0.01) and PKC (P<0.05) activities were also significantly increased. The inhibition of protein kinase C with GF109203X markedly reduced the phosphorylations of p38 MAPK and GSK-3betaand the expressions of cdk4 and cyclin D. In addition, pretreatment with GF109203X decreased the cell number in response to a high glucose level. CONCLUSION: These findings suggest that a high level of glucose increases vascular smooth muscle cell proliferation, with the possible mechanism further increases the G1 to S phase cell cycle progression via the activation of PKC, p38 MAPK and GSK-3beta.
Effect and Mechanism of Vascular Endothelial Growth Factor on Endothelial Nitric Oxide Synthase Expression in Aortic Endothelial Cells.
Soon Hee Lee, Jung Guk Kim, Joong Yeol Park, Sung Woo Ha, Bo Wan Kim
Korean Diabetes J. 2002;26(5):396-404.   Published online October 1, 2002
  • 915 View
  • 16 Download
AbstractAbstract PDF
Vascular endothelial growth factor (VEGF), a soluble angiogenic factor produced by many tumor and normal cells, is a potent angiogenic and vascular permeability factor. VEGF plays a key role in both pathological and physiological angiogenesis. There are many recent findings regarding the role of VEGF in diabetic microvascular and macrovascular diseases. Many approaches with VEGF-related therapies begin to treat and prevent these complications and have been used for the treatment of microvascular complications such as diabetic retinopathy, whereas VEGF agonists have been used to treat macrovascular complications such as myocardial infarction and peripheral limb ischemia. Nitric oxide (NO) is known to mediate many physiological and pathological functions, including modulation of vascular tone, permeability, and capillary growth. Recent reports indicate that NO may play an intimate role in VEGF signaling. Therefore, we hypothesized that the expression of eNOS may be regulated by VEGF. The objectives of the present study were to determine whether VEGF up-regulates the expression of endothelial NO synthase (eNOS) in endothelial cells and to elucidate the mechanism that mediate this response. METHODS: Endothelial cells were isolated from bovine aortae. The expression of eNOS was assessed by Northern blotting analysis. To evaluate the mechanism of VEGF-induced eNOS expression, endothelial cells were conditioned with VEGF and pretreated with phorbol-12-myristate acetate (PMA), a protein kinase C (PKC) activator, or GF109203X (GFX), a PKC inhibitor. The changes of eNOS gene expression. RESULTS: VEGF significantly increased the expression of eNOS mRNA in bovine aortic endothelial cells (BAEC) in time and dose dependent manners. PMA increased the expression of eNOS mRNA, as well as the VEGF-induced expression of eNOS mRNA in endothelial cells, while inhibition of the PKC activity, with the GFX blocked the upregulation of the VEGF-induced eNOS mRNA. CONCLUSION: The results suggest that VEGF upregulates eNOS gene expression in aortic endothelial cells, by a PKC dependent pathway and, eNOS may be important in the development of VEGF-induced angiopathy.
Effect of Protein Kinase C Inhibitor on Glucose Transporter-1 (GLUT1) Expression in Cultured Rat Mesangial Cells.
Ie Byung Park, Dae Ryong Cha, Dong Rim Kim, Sin Gon Kim, Dong Hyun Shin, Kyung Mook Choi, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi
Korean Diabetes J. 2001;25(3):218-229.   Published online June 1, 2001
  • 918 View
  • 17 Download
AbstractAbstract PDF
Recent studies have suggested that increased glucose uptake via GLUT1 may be a major determinant of glucose utilization and extracellular matrix formation in mesangial cells. This study was to evaluate the effect of protein kinase C inhibitor on glucose transporter-1 (GLUT1) expression in cultured rat mesangial cells. METHODS: The GLUT1 expression was evaluated in mesangial cells exposed to various glucose concentrations of media (5.5 mM, 15 mM or 30 mM) and incubation times (6 hr, 24 hr or 72 hr) by semiquantitative RT-PCR and western blot analysis. The effect of protein kinase C (PKC) inhibitor, calphostin C and phorbol 12-myristate 13-acetate (PMA) on GLUT1 expression was also evaluated under the same conditions. RESULTS: The GLUT1 mRNA expressions were significantly increased in MG (15 mM) and HG (30 mM) than those in NG (5.5 mM) with incubation of 6 hr, 24 hr and 72 hr, respectively. In HG media, the GLUT1 mRNA expression with incubation of 24 hr and 72 hr were significantly increased than that with incubation of 6 hr, respectively. In HG media, the GLUT1 mRNA expressions were significantly reduced in calphostin C and PMA treated groups compared with those in untreated groups. In western blot analysis of HG media, GLUT1 proteins were identified in PMA- or calphostin C-untreated group and PMA 6 hr treated group, but not identified in PMA 24 hr treated group and in calphostin C-treated groups with incubation of 6 hr and 24 hr. CONCLUSION: PKC inhibitors decrease glucose-induced GLUT1 expression under high glucose concentration in mesangial cells. These results suggest that PKC pathway may regulate GLUT1 expression under high glucose concentration in cultured rat mesangial cells.
Effect of Protein Kinase C Inhibitors on Expression of TGF-betamRNA in Cultured Mesangial Cells Under High Glucose Concentration.
Yoon Sang Choi, Dong Seop Choi
Korean Diabetes J. 1999;23(5):635-646.   Published online January 1, 2001
  • 813 View
  • 17 Download
AbstractAbstract PDF
Diabetic nephropathy is characterized by hypertrophy of both glomerular and tubular elements, thickening of the glomerular and tubular basement membranes, progressive accumulation of extracellular matrix components in mesangium, and tubulointerstitial fibrosis. Hyperglycemia increases the level of diacylglycerol (DAG) and activates protein kinase C (PKC) in mesangial cells and other vascular tissues. PKC activation regulates a number of vascular functions such as vascular permeability, contractility, cellular proliferation, basement membrane synthesis, signal transduction mechanisms for hormones and growth factors, In addition, glomerular mesangial cells play an important role in the development of diabetic nephropathy. Mesangial cells have many functions such as contractile properties, phagocytosis of macromolecules, synthesis of matrix proteins, and production of and response to growth factors (e.g., PDGF, TGF beta). Also, these growth factors play important roles for mesangial cell proliferation and in pathophysiology of diabetic nephropathy. Specifically, TGF beta is a key mediator in development of diabetic nephropathy. This study was performed to evaluate the relationship between PKC activation and TGF f3 production in mesangial cells under high glucose condition. METHODS: The expression of the TGF beta mRNA was evaluated in cultured human mesangial cells by semiquantitive RT-PCR, under varying degree of glucose concentrations (5 mM, 10 mM, 30 mM) with and without treatment of PKC inhibitors (calphostin C, Vitamin-E). RESULT: In control group (no treatment), ratio of TGF beta/beta-aetin mRNA in 5mM, 10mM, 30mM glucose were 1.694+/-0.223, 3.383+/-2.089, 5,474+/-1.74S, respectively. In calphostin C treated group, ratio of TGF beta/beta-actin mRNA in 5mM, 10mM, 30mM glucose were 1.457+/-0,322, 1.379+/-0.138, 1.205+/-0.050, respectively. In vitamin E treated group, ratio of TGF beta/beta-actin mRNA in 5mM, 10rnM, 30mM glucose were 1.198+/-0.081, 1.995+/-1.625, O.S04+/-0.570, respectively. In 10mM glucose concentration, ratios of TGF beta/beta-actin mRNA were reduced in calphostin C and vitamin E treated groups, compared with those in control group. But, there were no statistical significancies (p=0.191, 0.208). In high glucose concentration (30mM), ratios of TGF /3/f3-actin mRNA were significantly reduced in calphostin C and vitamin E treated groups compared with those in control group (p<0.05), respectively. CONCLUSIONS: These results indicate that high glucose concentration induce TGF beta expression in eultured mesangial cells through PKC activation. This suggests that selective PKC beta isoform inhibitors may be useful for treatment and prevention of diabetie nephropathy.
Effect of Hyperglycemia on Internalization of Insulin-receptor Complexes in Human Umbilical Vein Endothelial Cells.
Ki Ho Song, Yu Bae Ahn, Je Ho Han, Soon Jip Yoo, Kun Ho Yoon, Moo Il Kang, Bong Yun Cha, Kwang Woo Lee, Ho Young Son, Sung Koo Kang
Korean Diabetes J. 1999;23(2):131-141.   Published online January 1, 2001
  • 1,078 View
  • 20 Download
AbstractAbstract PDF
It is well known that hyperglycemia activates protein kinase C (PKC) in vascular endothelial cells. However, the effect of hyperglycemia on internalization and recycling of insulin receptors by insulin in endothelial cells has not been examined thus far. METHODS: Human umbilical vein endothelial cells (HUVECs) were isolated from healthy, pregnant women. Confluent HUVECs were incubated in a culture media containing either 5 (NG group) or 25 mM glucose (HG group) for 4 days. Then, we measured the insulin binding, internalization and recycling of the insulin receptor and release of internalized insulin into the media. RESULTS: There was no difference in binding of 0.17 nM 125I-insulin between the two groups. However, the amount of internalized 125I-insulin, determined by the aeid washing method, was significantly greater in the HG group compared to the NG group. The addition of 10 pM 1-(5-isoquino-linesulfonyl)-2-methyl-piperazine (H7), a PKC inhibitor, to the HG group prevented the increase of internalization in 125I-insulin. In addition, preincubation with unlabeled insulin resulted in a decrease of 125I-insulin binding to a greater extent in the HG group compared with the NG group, indicating that high glucose levels increased internalizntion of insulin receptors. The high glucose-induced increase in internalization of insulin receptors was prevented by an addition of H7. Recycling of insulin receptors to the cell surface was not affected by high glucose. Internalized 125I-insulin released into media with time. The released amount of I-insulin in the HC group tended to be greater compared to the NG group. CONCLUSION: These results suggest that hyperglycemia may increase internalization of the insulin-receptor complexes in vascular endothelial cells through PKC activation.

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer